Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7876549 | 0.80 | SIGMAR1 (0.53) | SIGMAR1HTR2CMAPTHTR6HTR2A | |
| SCHEMBL18446234 | 0.77 | ITK (0.56) | CHEK1 | |
| SCHEMBL18445668 | 0.77 | ITK (0.55) | CHEK1KDR | |
| SCHEMBL7859749 | 0.77 | HTR6 (0.45) | SIGMAR1HTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL8819830 | 0.77 | HTR6 (0.43) | SIGMAR1HTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL2085643 | 0.77 | RAB9A (0.50) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL31181951 | 0.77 | RAB9A (0.50) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL8820703 | 0.76 | SIGMAR1 (0.42) | SIGMAR1HTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL1174412 | 0.75 | RAB9A (0.49) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL18454216 | 0.75 | ITK (0.48) | SIGMAR1HTR2CHTR6HTR2ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1261363-A | Process for the manufacture of sertindole | LUNDBECK & CO AS H (DK) | 2000-07-26 | — | — | CN | claimed |
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-7371769-B2 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-05-13 | — | — | US | disclosed |
| EP-1828168-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | Solvay Pharmaceuticals B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| US-20070066634-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-22 | — | — | US | disclosed |
| WO-2006061373-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122206-A1 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| EP-1200072-A2 | METHOD OF TREATING PSYCHOTIC DISORDERS | Solvay Pharmaceuticals B.V. (NL) | 2002-05-02 | — | — | EP | disclosed |
| WO-2000069424-A3 | METHOD OF TREATING PSYCHOTIC DISORDERS | SOLVAY PHARM BV (NL) | 2001-06-07 | — | — | WO | disclosed |
| EP-1077213-A2 | Inhibition of serotonin reuptake | ELI LILLY AND COMPANY (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-2000069424-A2 | METHOD OF TREATING PSYCHOTIC DISORDERS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2000-11-23 | — | — | WO | disclosed |
| US-6046215-A | A PIPERIDINYLBENZOTHIOPHENES USEFUL FOR TRATING BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-5846982-A | Inhibition of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0812826-A1 | 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0169148-B1 | INDOLE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122206-A1 | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SLC6A3, HTR3C, DRD3 | SIGMAR1 125/4885HTR2C 5/4885KDM4E 4257/4885 |
| US-20070066634-A2 | TETRAHYDROPYRIDIN-4-YL INDOLES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SLC6A3, HTR3C, DRD3 | SIGMAR1 125/4885HTR2C 5/4885KDM4E 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.